BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: OUTCOMES IN ROUTINE CLINICAL PRACTICE

C. Mariano1, M. Garín2, C. Ilitiguez3, E. Díez2, C. Díez2, L. Gómez-Lechón4, J. Martín5, M. Corteguera2, J. Martinez2, J. Cabezas2, T. Pérez2, Hospital León, León, Spain

Background: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a wide range of clinical manifestations. The persistence of activity of the disease and the prolonged use of corticosteroids are amongst the main predictors of accumulated organ damage in patients with SLE. Therefore, we need new strategies to induce long-lasting remission and minimise the adverse effects of standard medications.

Objectives: To assess the effectiveness and safety of Belimumab in actual clinical practice during the first year of treatment in patients with SLE.

Methods: Retrospective observational study of patients treated with Belimumab. This study involves 6 hospitals in Castilla y León (Spain). It collects clinical and analytical data before the start of Belimumab, and 6 and 12 months after the initiation of the therapy. The data collected include the daily dose of prednisone received at different time points and the activity of the disease was classified as mild, moderate and severe based on the SELENA-SLEDAI index. A reduction from baseline of 3 points on the SELENA-SLEDAI index means significant symptomatic improvement.

Results: Among the twenty-five patients were included, with a mean age of 43.7 ±12.2 years, 72% were female and 96% Caucasian. The average time from diagnosis of SLE to Belimumab infusion was 9.5 ±7.1 years; 32% were diagnosed with SLE ≤5 years ago. Up to 56% of the patients had moderate disease activity and only 8% patients had very high activity of the disease. All but one of the patients had previously received an immunosuppressant (azathioprine in 50% of the cases) and 16% of the sample had not responded to rituximab. The most frequent reasons for initiating Belimumab were an ineffective previous treatment regimen (60%), the need to decrease steroid use (58%), and worsening patient condition (52%); whereas the most frequent manifestation of SLE in these patients were arthritids (44%), followed by mucocutaneous (20%) and immunologic (20%) findings. As for immunologic markers of activity, DNA was elevated by 40% and 68% of the patients showed hypocomplementemia, that dropped to 24% in both cases at 12 months. The mean score of the SELENA-SLEDAI index decreased from 5.8 ±2.4 in baseline to 2.4 ±1.1 in 6 months and to 5.1 ±2.4 in 12 months of follow-up. A reduction in the initial mean steroid dose was also observed from 20 mg/day to 8.9 mg/day and 6.4 mg/day at 6 and 12 months respectively. Hence, the dose of steroid was reduced by 68% during the first year (p=0.06). This reduction was clinically significant, but it did not reach statistical significance in our study. Two patients (8%) had discontinued Belimumab within the first 6 months of therapy (1 pregnancy and 1 worsening proteinuria); 34.7% had discontinued it within the first 12 months, mostly due to ineffectiveness (62.5%). Two patients with severe renal involvement (≥1 g proteinuria/24 hour) were treated with Belimumab, allowing to reduce the steroids to a low dose (<7.5 mg/day) at 12 months.

Conclusions: Belimumab appears to be effective, reducing disease activity as measured by the SELENA-SLEDAI index and also, the mean dose of steroids needed, mainly after 12 months of treatment. No significant adverse effects were reported as previous studies have shown.

Disclosure of Interest: None declared

AB0509
KZR-616, A SELECTIVE INHIBITOR OF THE IMMUNOPROTEASOME, SHOWS A PROMISING SAFETY AND TARGET INHIBITION PROFILE IN A PHASE I, DOUBLE-BLIND, SINGLE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) STUDY IN HEALTHY VOLUNTEERS

J. Lickliter1, D. Bomba2, J. Andersen2, A. Far3, G. Koo4, B. Wang3, 1 Nucleus Network, Melbourne, Victoria, Australia; 2 Kezar Life Sciences, South San Francisco, California, USA

Background: Proteasome inhibition is a standard of care for plasma cell malignancies. Bortezomib targets the constitutive proteasome and immunoproteasome, and is effective in the treatment of Systemic Lupus Erythematosus (SLE) and lupus nephritis (LN), but is associated with hematologic (e.g. thrombocytopenia) and constitutional (e.g. peripheral neuropathy) adverse events (AEs). Objectives: We report the safety, pharmacokinetics (PK), pharmacodynamics (PD) and immunomodulatory effects of KZR-616, a first-in-class selective inhibitor of the immunoproteasome, in healthy volunteers (HV) following single and repeat subcutaneous (SC) administration.

Methods: Cohorts (6 drug:2 placebo) received single or 4 weekly SC doses. Safety assessments, PK and PD were measured to Day 7 (SAD) or Day 28 (MAD); SAD cohorts included 7.5, 15, 30 and 60 mg (SC), MAD cohorts included 30, 60 and 120 mg, and 2 intrasubject escalation cohorts with 1 dose at 30 mg and 3 doses at 45 mg. PK was measured by LC/MS². PD was measured using enzymatic and active site binding assays. Inflammatory cytokine release was measured following ex vivo stimulation of whole blood in HV receiving placebo or 45 mg KZR-616.

Results: 32 HV (24:8) were enrolled in 4 SAD cohorts. The most common AEs were injection site reactions (ISRs), which were generally mild and transient. No clinically-significant (CS) laboratory or ECG abnormalities and no dose limiting toxicities were observed in the SAD subjects. Following SC administration, drug exposure increased dose proportionally and was characterised by rapid absorption (Tmax=15–30 min) and clearance (T1/2~2 hours). Inhibition of the immunoproteasome exceeded 80% at >30 mg with significant recovery noted over 7 days. Constitutive proteasome inhibition was <37% in all cohorts.

40 HV (30:10) were enrolled in 5 SC MAD cohorts. In the initial cohort of 60 mg, a systemic drug reaction (chills, elevated heart rate, nausea) occurred ~8 hours after the first dose in 4 subjects. Dosing for this cohort was stopped. Subsequent cohorts (initiated at 30 mg) received prophylactic treatment with antihistamines and sildenfin 1 hour prior to the first and second dose. No similar AEs occurred when repeat dosing of 45 mg. Go laboratory or ECG abnormalities were seen in the remaining MAD cohorts. ISRs did not appear to increase in severity or frequency with repeat dosing. There were no AEs of peripheral neuropathy, and 45 mg was well tolerated across 3 cohorts.

Consistent PK was noted following repeat administration and no drug accumulation was observed. At 45 mg, inhibition of 2 key subunits of the immunoproteasome, LMP7 and LMP2, was >95% and >70%, respectively. Reduced ex vivo stimulated production of multiple cytokines (IL-23, IL-6, TNF-a, IL-17) was noted in subjects receiving repeat administration of 45 mg KZR-616.